PSU Profiles
Keywords
Last Name
Institution

Gavin Robertson

TitleProfessor
InstitutionCollege of Medicine
DepartmentPharmacology
Address500 University Drive Hershey PA 17033
Mailbox: CH74
Phone7175318098

 Overview 
 overview
PREFERRED TITLE/ROLE:

Associate Professor of Pharmacology, Pathology, and Dermatology, Associate Director for Translational Research, Director; Melanoma Center, Director; Melanoma Therapeutics Program

SECONDARY APPOINTMENT(S)/ INSTITUTE(S)/ CENTER(S):

Pathology, Dermatology, Surgery, Penn Sate Hershey Cancer Institute, The Huck Institutes of the Life Sciences

GRADUATE PROGRAM AFFILIATIONS:

Genetics, Pharmacology, Cell and Molecular Biology, Integrative Biosciences, Biomedical Sciences: Translational Therapeutics Option

EDUCATION:

Ph.D., University of California, Riverside, 1997
Postdoctoral Training, Ludwig Institute for Cancer Research, San Diego, 1997-2000

NARRATIVE:

Dr. Robertson's research program focuses on malignant melanoma, which is the most deadly form of skin cancer. The central goal of his program is to unravel the biology and signaling pathways involved in melanoma tumor development in order to develop the next generation of therapeutic agents to treat this disease. Specifically, it involves identification and validation of novel therapeutic targets, discovery & development of new therapies and clinical evaluation of these drugs in patients. Generally, the types of studies occurring the Robertson laboratory are as follows. First, genetic, cell culture, animal, as well as human models are used to identify and validate the involvement of candidate melanoma causing genes in this disease. A recent example is the discovery of Akt3 involvement in ~70% of human melanomas. Second, drug screens and medicinal chemistry are used to identify and develop new therapeutic agents. A recent example is the melanoma treating drug ISC-4, which targets Akt3 signaling. Third, nanotechnology and bioengineering are used to better deliver experimental agents into cancer cells. A recent example of this is the use of nanoliposomes and ultrasound that deliver therapeutic siRNA into melanoma cells. Finally, agents are tested in the clinic for toxicity and tumor inhibitory efficacy. A recent example is a killed mycobacterium called CADI-5 that is being evaluated in clinical trials. The ultimate goal of Dr. Robertson's translational research program is to develop better therapeutics for the treatment of melanoma based on the biology of the disease.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sadashiva MP, Gowda R, Wu X, Inamdar GS, Kuzu OF, Rangappa KS, Robertson GP, Gowda DC. A non-cytotoxic N-dehydroabietylamine derivative with potent antimalarial activity. Exp Parasitol. 2015 Aug; 155:68-73.
    View in: PubMed
  2. Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther. 2015 May 4; 16(5):662-70.
    View in: PubMed
  3. Gowda R, Madhunapantula SV, Sharma A, Kuzu OF, Robertson GP. Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Mol Cancer Ther. 2014 Oct; 13(10):2328-40.
    View in: PubMed
  4. Kardos GR, Dai MS, Robertson GP. Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res. 2014 Sep; 27(5):801-12.
    View in: PubMed
  5. Mumford BS, Robertson GP. Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther. 2014 Apr; 18(2):175-83.
    View in: PubMed
  6. Gowda R, Madhunapantula SV, Kuzu OF, Sharma A, Robertson GP. Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther. 2014 Jul; 13(7):1679-89.
    View in: PubMed
  7. Kuzu OF, Gowda R, Sharma A, Robertson GP. Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. Mol Cancer Ther. 2014 Jul; 13(7):1690-703.
    View in: PubMed
  8. Dluzen DF, Sun D, Salzberg AC, Jones N, Bushey RT, Robertson GP, Lazarus P. Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p. J Pharmacol Exp Ther. 2014 Mar; 348(3):465-77.
    View in: PubMed
  9. Madhunapantula SV, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3a as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2013 Nov; 26(6):886-99.
    View in: PubMed
  10. Khanna P, Chung CY, Neves RI, Robertson GP, Dong C. CD82/KAI expression prevents IL-8-mediated endothelial gap formation in late-stage melanomas. Oncogene. 2014 May 29; 33(22):2898-908.
    View in: PubMed
  11. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013 Jul 1; 12(13):2132-43.
    View in: PubMed
  12. Sharma A, Madhunapantula SV, Gowda R, Berg A, Neves RI, Robertson GP. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma. Am J Pathol. 2013 Apr; 182(4):1151-62.
    View in: PubMed
  13. Evans MS, Madhunapantula SV, Robertson GP, Drabick JJ. Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol. 2013; 779:223-55.
    View in: PubMed
  14. Singh S, Sharma A, Robertson GP. Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns. Cancer Res. 2012 Nov 15; 72(22):5663-8.
    View in: PubMed
  15. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther. 2013 Jan; 12(1):3-15.
    View in: PubMed
  16. Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther. 2012 Jul; 13(9):756-65.
    View in: PubMed
  17. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012 Mar; 25(2):259-74.
    View in: PubMed
  18. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther. 2011 Dec 15; 12(12):1032-49.
    View in: PubMed
  19. Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol. 2012 Jan; 8(1):47-69.
    View in: PubMed
  20. Sudol M, Fritz JL, Tran M, Robertson GP, Ealy JB, Katzman M. Evaluation of a system to screen for stimulators of non-specific DNA nicking by HIV-1 integrase: application to a library of 50,000 compounds. Antivir Chem Chemother. 2011; 22(2):67-74.
    View in: PubMed
  21. Madhunapantula SV, Robertson GP. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res. 2011; 2011:327923.
    View in: PubMed
  22. Chung CY, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma prevention using topical PBISe. Cancer Prev Res (Phila). 2011 Jun; 4(6):935-48.
    View in: PubMed
  23. Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, Robertson GP, Yan L, Rubin E, Yang JM. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res. 2011 Apr 1; 71(7):2654-63.
    View in: PubMed
  24. Zhang P, Ozdemir T, Chung CY, Robertson GP, Dong C. Sequential binding of aVß3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J Immunol. 2011 Jan 1; 186(1):242-54.
    View in: PubMed
  25. Madhunapantula SV, Gowda R, Inamdar GS, Robertson GP. In situ photoimmunotherapy: a new hope for cutaneous melanoma patients. Cancer Biol Ther. 2010 Dec 1; 10(11):1088-90.
    View in: PubMed
  26. Nguyen N, Sharma A, Nguyen N, Sharma AK, Desai D, Huh SJ, Amin S, Meyers C, Robertson GP. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. Cancer Prev Res (Phila). 2011 Feb; 4(2):248-58.
    View in: PubMed
  27. Madhunapantula SV, Mosca P, Robertson GP. Steroid hormones drive cancer development. Cancer Biol Ther. 2010 Oct 15; 10(8):765-6.
    View in: PubMed
  28. Huh SJ, Chen YL, Friedman SL, Liao J, Huang HJ, Cavenee WK, Robertson GP. KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst. 2010 Aug 4; 102(15):1131-47.
    View in: PubMed
  29. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010 Jul 15; 70(14):6071-82.
    View in: PubMed
  30. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010 Sep 1; 80(5):624-37.
    View in: PubMed
  31. Mathew R, Jia W, Sharma A, Zhao Y, Clarke LE, Cheng X, Wang H, Salli U, Vrana KE, Robertson GP, Zhu J, Wang S. Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J. 2010 Aug; 24(8):2702-15.
    View in: PubMed
  32. Desai D, Madhunapantula SV, Gowdahalli K, Sharma A, Chandagaludoreswamy R, El-Bayoumy K, Robertson GP, Amin S. Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer. Bioorg Med Chem Lett. 2010 Mar 15; 20(6):2038-43.
    View in: PubMed
  33. Sudol M, Tran M, Nowak MG, Flanagan JM, Robertson GP, Katzman M. A nonradioactive plate-based assay for stimulators of nonspecific DNA nicking by HIV-1 integrase and other nucleases. Anal Biochem. 2010 Jan 15; 396(2):223-30.
    View in: PubMed
  34. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009 Aug; 22(4):400-19.
    View in: PubMed
  35. Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009 Aug; 22(4):388-99.
    View in: PubMed
  36. Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev. 2009 Jan-Feb; 18(1):55-65.
    View in: PubMed
  37. Dong C, Robertson GP. Immunoediting of leukocyte functions within the tumor microenvironment promotes cancer metastasis development. Biorheology. 2009; 46(4):265-79.
    View in: PubMed
  38. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem. 2008 Dec 25; 51(24):7820-6.
    View in: PubMed
  39. Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008 Dec; 8(12):4116-21.
    View in: PubMed
  40. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008 Sep 15; 68(18):7638-49.
    View in: PubMed
  41. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008 Jun 1; 14(11):3571-81.
    View in: PubMed
  42. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008 May 1; 68(9):3429-39.
    View in: PubMed
  43. Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Ther. 2008 May; 7(5):1297-308.
    View in: PubMed
  44. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 2008 Jan 1; 68(1):5-8.
    View in: PubMed
  45. Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology. 2008 Jan 14; 243(1-2):236-43.
    View in: PubMed
  46. Sharma A, Robertson GP. Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents. Curr Protoc Pharmacol. 2007 Sep; Chapter 14:Unit 14.6.
    View in: PubMed
  47. Liang S, Sharma A, Peng HH, Robertson G, Dong C. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 2007 Jun 15; 67(12):5814-20.
    View in: PubMed
  48. Robertson GP. Mig-7 linked to vasculogenic mimicry. Am J Pathol. 2007 May; 170(5):1454-6.
    View in: PubMed
  49. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007 Apr 15; 67(8):3626-36.
    View in: PubMed
  50. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 2006 Aug 15; 66(16):8200-9.
    View in: PubMed
  51. Croushore JA, Blasiole B, Riddle RC, Thisse C, Thisse B, Canfield VA, Robertson GP, Cheng KC, Levenson R. Ptena and ptenb genes play distinct roles in zebrafish embryogenesis. Dev Dyn. 2005 Dec; 234(4):911-21.
    View in: PubMed
  52. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005 Jun; 24(2):273-85.
    View in: PubMed
  53. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 2005 Mar 15; 65(6):2412-21.
    View in: PubMed
  54. Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene. 2004 Dec 8; 343(1):69-78.
    View in: PubMed
  55. Robertson GP, Sargent L, Nelson MA. Positional approaches to cancer genetics. Methods Mol Biol. 2003; 222:339-64.
    View in: PubMed
  56. Miele ME, Robertson G, Lee JH, Coleman A, McGary CT, Fisher PB, Lugo TG, Welch DR. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Mol Carcinog. 1996 Apr; 15(4):284-99.
    View in: PubMed
Robertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_